Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Acrux.
RELATED STOCKHEAD STORIES
Experts
MoneyTalks: This biotech focused fund explains why it invested $15m in these 2 ASX stocks
News
Directors’ Trades: Which ASX company director put another $3.6 million into their gold stock?
News
Last Orders: What you might have missed on the ASX today
News
10 at 10: These ASX stocks are showing off their determination this morning
News
Rise and Shine: What you need to know before the ASX opens
Stockhead TV
StockTalk: Drug delivery tech offers patients, investors massive upside
Health & Biotech
Drug delivery technology: How it works, and the ASX companies with plans to capitalise
Health & Biotech
All of 1300 Smiles’ Jobkeeper subsidy has gone on its dividend
Health & Biotech
Dr Boreham’s Crucible: Dimerix not putting all its eggs in one basket
News
ASX Small Cap Lunch Wrap: Who’s keeping it ‘briefs’ today?
News
10 at 10: These ASX stocks are back with a bang this morning
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
The pandemic could be a watershed moment for wellness products
News
Lunchtime ASX small cap wrap: who’s leaping higher today
Health & Biotech
Acrux poked an $8.7bn bear and now it’s fighting back; shares drop 24pc
Health & Biotech
A year after cold shower Acrux rebuild gets underway with first generic drug
Health & Biotech